ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Takeda, Ovid to co-develop TAK-935 for paediatric epilepsies
firstwordpharma
January 19, 2017Takeda and Ovid Therapeutics on Wednesday announced a global collaboration to jointly develop and commercialise the Japanese company's experimental selective CH24H inhibitor TAK-935 for the treatment of rare paediatric epilepsies.
Pharma Sources Insight January 2025
